Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.
You may also be interested in...
DeBethizy discusses the firm’s unique origins, its work with AstraZeneca and what’s ahead for the Raleigh, N.C.-based company.
Glaxo partners with Targacept in potential $1.5 billion deal on neuronal nicotinic receptor therapeutics for pain, smoking cessation, obesity, addiction and Parkinson’s.
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.